Potassium phosphate and sodium phosphate

Follow all directions on your prescription label. Do not take this medicine in larger or smaller amounts or for longer than recommended.

Take this medicine with a full glass of water.

Potassium phosphate and sodium phosphate works best if you take it with meals and at bedtime.

While using this medicine, you may need frequent blood or urine tests.

The powder form must be mixed with water before you take it. Mix 1 packet of the powder with about 1/3 cup (2.5 ounces) of water and stir until completely dissolved. Swallow the mixture right away after mixing. Do not save for later use.

The tablet form may need to be dissolved in water, or swallowed whole. Carefully follow any dosing instructions provided with your medicine.

If you have a history of kidney stones, it is possible that you will pass old stones after starting treatment with potassium phosphate and sodium phosphate.

Store at room temperature away from moisture, heat, and light. Keep the bottle tightly closed when not in use.

Other drugs may interact with potassium phosphate and sodium phosphate, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell each of your health care providers about all medicines you use now and any medicine you start or stop using.

• Neutra-Phos
• Sodium Phosphate and Potassium Phosphate

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Powder for solution, oral:

Phos-NaK: Dibasic potassium phosphate, monobasic potassium phosphate, dibasic sodium phosphate, and monobasic sodium phosphate per packet (100s) [sugar free; equivalent to elemental phosphorus 250 mg (8 mmol), sodium 160 mg (6.9 mEq), and potassium 280 mg (7.1 mEq) per packet; fruit flavor]

Tablet, oral:

Av-Phos 250 Neutral: Monobasic potassium phosphate 155 mg, dibasic sodium phosphate 852 mg, and monobasic sodium phosphate 130 mg [equivalent to elemental phosphorus 250 mg (8 mmol), sodium 298 mg (13 mEq), and potassium 45 mg (1.1 mEq)]

K-Phos Neutral: Monobasic potassium phosphate 155 mg, dibasic sodium phosphate 852 mg, and monobasic sodium phosphate 130 mg [equivalent to elemental phosphorus 250 mg (8 mmol), sodium 298 mg (13 mEq), and potassium 45 mg (1.1 mEq)]

K-Phos No. 2: Potassium acid phosphate 305 mg and sodium acid phosphate 700 mg [equivalent to elemental phosphorus 250 mg (8 mmol), sodium 134 mg (5.8 mEq), and potassium 88 mg (2.3 mEq)]

Phospha 250 Neutral: Monobasic potassium phosphate 155 mg, dibasic sodium phosphate 852 mg, and monobasic sodium phosphate 130 mg [equivalent to elemental phosphorus 250 mg (8 mmol), sodium 298 mg (13 mEq), and potassium 45 mg (1.1 mEq)]

Phospho-Trin 250 Neutral: Monobasic potassium phosphate 155 mg, dibasic sodium phosphate 852 mg, and monobasic sodium phosphate 130 mg [equivalent to elemental phosphorus 250 mg (8 mmol), sodium 298 mg (13 mEq), and potassium 45 mg (1.1 mEq)]

Virt-Phos 250 Neutral: Monobasic potassium phosphate 155 mg, dibasic sodium phosphate 852 mg, and monobasic sodium phosphate 130 mg [equivalent to elemental phosphorus 250 mg (8 mmol), sodium 298 mg (13 mEq), and potassium 45 mg (1.1 mEq)]

Concerns related to adverse effects:

• Laxative effect: A mild laxative effect may occur within the first few days of therapy; if the laxative effect persists, reduce the dose or discontinue use until diarrhea improves.

Disease-related concerns:

• Adrenal insufficiency: Use with caution in patients with severe adrenal insufficiency (eg, Addison disease)

• Cardiac disease: Use with caution in patients with cardiac disease, including heart failure (especially patients receiving digoxin) and hypertension.

• Dehydration: Use with caution in patients with acute dehydration.

• Edema: Use with caution in patients with peripheral or pulmonary edema.

• Hepatic impairment: Use with caution in patients with cirrhosis or severe hepatic impairment.

• Hypernatremia: Use with caution in patients with hypernatremia.

• Myotonia congenita: Use with caution in patients with myotonia congenita.

• Pancreatitis: Use with caution in patients with acute pancreatitis.

• Parathyroid disease: Use with caution in patients with hypoparathyroidism.

• Preeclampsia: Use with caution in pregnant patients with preeclampsia of pregnancy.

• Renal calculi: Patients with renal calculi may pass preformed stones when phosphate therapy is initiated.

• Renal impairment: Use with caution in patients with renal impairment or chronic renal disease; use is contraindicated in patient with severe renal impairment (<30% of normal).

• Rickets: Use with caution in patients with rickets; may increase the risk of extraskeletal calcification.

• Tissue breakdown: Use with caution in patients with extensive tissue breakdown (eg, severe burns).

Concurrent drug therapy issues:

• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.

Serum potassium, sodium, calcium, phosphorus, magnesium (to facilitate potassium repletion), and renal function at periodic intervals

• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)

• Patient may experience abdominal pain, vomiting, or nausea. Have patient report immediately to prescriber signs of high potassium (abnormal heartbeat, confusion, dizziness, passing out, weakness, shortness of breath, or numbness or tingling feeling), tachycardia, severe diarrhea, severe headache, muscle cramps, seizures, shortness of breath, excessive weight gain, swelling of arms or legs, severe loss of strength and energy, bone pain, joint pain, feeling of heaviness in arms or legs, urinary retention, or increased thirst (HCAHPS).

• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.

Intended Use and Disclaimer:Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.